Literature DB >> 11053442

Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0.

P Lomonte1, K F Sullivan, R D Everett.   

Abstract

Cells infected by herpes simplex virus type 1 in the G2 phase of the cell cycle become stalled at an unusual stage of mitosis defined as pseudoprometaphase. This block correlates with the viral immediate-early protein ICP0-induced degradation of the centromere protein CENP-C. However, the observed pseudoprometaphase phenotype of infected mitotic cells suggests that the stability of other centromere proteins may also be affected. Here, we demonstrate that ICP0 also induces the proteasome-dependent degradation of the centromere protein CENP-A. By a series of Western blot and immunofluorescence experiments we show that the endogenous 17-kDa CENP-A and an exogenous tagged version of CENP-A are lost from centromeres and degraded in infected and transfected cells as a result of ICP0 expression. CENP-A is a histone H3-like protein associated with nucleosome structures in the inner plate of the kinetochore. Unlike fully transcribed lytic viral DNA, the transcriptionally repressed latent herpes simplex virus type 1 genome has been reported to have a nucleosomal structure similar to that of cellular chromatin. Because ICP0 plays an essential part in controlling the balance between the lytic and latent outcomes of infection, the ICP0-induced degradation of CENP-A is an intriguing feature connecting different aspects of viral and/or cellular genome regulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053442     DOI: 10.1074/jbc.M008547200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  94 in total

1.  Requirements for the nuclear-cytoplasmic translocation of infected-cell protein 0 of herpes simplex virus 1.

Authors:  P Lopez; C Van Sant; B Roizman
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1.

Authors:  Ryan Hagglund; Bernard Roizman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Recruitment of herpes simplex virus type 1 immediate-early protein ICP0 to the virus particle.

Authors:  Kevin Maringer; Gillian Elliott
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

4.  Reversal of heterochromatic silencing of quiescent herpes simplex virus type 1 by ICP0.

Authors:  Michael W Ferenczy; Neal A DeLuca
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

5.  An E3 ubiquitin ligase prevents ectopic localization of the centromeric histone H3 variant via the centromere targeting domain.

Authors:  Prerana Ranjitkar; Maximilian O Press; Xianhua Yi; Richard Baker; Michael J MacCoss; Sue Biggins
Journal:  Mol Cell       Date:  2010-11-12       Impact factor: 17.970

Review 6.  Putting CENP-A in its place.

Authors:  Madison E Stellfox; Aaron O Bailey; Daniel R Foltz
Journal:  Cell Mol Life Sci       Date:  2012-06-23       Impact factor: 9.261

7.  The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity.

Authors:  C Van Sant; R Hagglund; P Lopez; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

8.  A PSHaver for centromeric histones.

Authors:  H Diego Folco; Arshad Desai
Journal:  Mol Cell       Date:  2010-11-12       Impact factor: 17.970

9.  During lytic infections, herpes simplex virus type 1 DNA is in complexes with the properties of unstable nucleosomes.

Authors:  Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

10.  Herpes simplex virus type 1 infection induces the stabilization of p53 in a USP7- and ATM-independent manner.

Authors:  Chris Boutell; Roger D Everett
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.